RHÖN-KLINIKUM AG reports record growth and €1.7B revenue in 2025

RHÖN-KLINIKUM AG has reported strong financial and operational growth for 2025. The healthcare group treated nearly a million patients while expanding its services and investing in advanced medical technology. Shareholders are set to receive a dividend as the company prepares for further expansion in 2026. In 2025, RHÖN-KLINIKUM AG saw its consolidated revenues rise by 6.8% to €1,704.7 million. The company also recorded an EBITDA of €105.9 million and a consolidated profit of €36.3 million. Patient numbers climbed by 2.5%, reaching 938,650 over the year.

The group expanded its care offerings with several key developments. A joint breast centre was opened in Gießen and Marburg, raising the standard for oncological treatment in Hesse. Investments included a new laboratory line in Gießen, advanced cardiac catheter technology in Marburg, and a radiotherapy system for cancer care in Bad Berka. Additionally, the company introduced photon counting computer tomography, becoming the only hospital group in Germany with three of the latest-generation systems in operation. Looking ahead, RHÖN-KLINIKUM AG expects revenues of around €1.7 billion for 2026. EBITDA is forecasted to fall between €110 million and €125 million. The Supervisory Board and Board of Management have proposed a dividend of €0.20 per share for shareholders.

The company's 2025 results reflect growth in patient care, revenue, and technological advancements. With new facilities and high-tech medical investments, RHÖN-KLINIKUM AG is positioning itself for continued expansion. Shareholders will vote on the proposed dividend at the next general meeting.